Skip to main content
SpringerLink
Log in
Book cover

Radiotherapy for Hodgkin Lymphoma pp 67–79Cite as

Pediatric Hodgkin Lymphoma, the Rationale for Radiation Therapy

  • Chapter
  • First Online:

Abstract

The challenge in pediatric Hodgkin lymphoma (HL) is to continue progress in its curability while diminishing the risk for delayed toxicities that has undermined this progress. Pediatric HL is highly curable, with a 10-year actuarial survival rate of 85–97% in early-stage disease, and 70–90% in advanced-stage disease. The most profound morbidities that prompted trials of combined chemotherapy and low-dose radiation therapy (RT) were musculoskeletal and soft tissue growth impairment, as well as delayed myocardial failure or infertility from commonly used chemotherapy agents. Contemporary pediatric HL treatment employs multiagent chemotherapy, with dose intensity tailored according to patients’ risk factors, and selected use of low-dose radiation therapy to lymph node regions initially involved (i.e., involved-field radiation therapy, IFRT). The goal is to refine therapy in a rare disease in which long-time intervals are necessary to observe an adequate number of events (treatment failure or late effects) to answer judicious questions.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Adams MJ, Lipsitz SR, Colan SD et al (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22:3139–3148

    Article  PubMed  Google Scholar 

  • Aleman BM, Raemaekers JM, Tirelli U et al (2003a) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348:2396–2406

    Article  PubMed  Google Scholar 

  • Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al (2003b) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439

    Article  PubMed  Google Scholar 

  • Alm El-Din MA, Hughes KS, Finkelstein DM et al (2009) Breast cancer after treatment of Hodgkin’s lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys 73:69–74

    Article  PubMed  Google Scholar 

  • Bader SB, Weinstein H, Mauch P et al (1993) Pediatric stage IV Hodgkin disease. Long-term survival. Cancer 72:249–255

    Article  PubMed  CAS  Google Scholar 

  • Bayle-Weisgerber C, Lemercier N, Teillet F et al (1984) Hodgkin’s disease in children. Results of therapy in a mixed group of 178 clinical and pathologically staged patients over 13 years. Cancer 54:215–222

    Article  PubMed  CAS  Google Scholar 

  • Bhatia S, Yasui Y, Robison LL et al (2003) High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol 21:4386–4394

    Article  PubMed  Google Scholar 

  • Bonadonna G, Valagussa P, Santoro A (1985) Prognosis of bulky Hodgkin’s disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv 4:439–458

    PubMed  CAS  Google Scholar 

  • Bramswig JH, Heimes U, Heiermann E et al (1990) The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin’s disease during childhood or adolescence. Cancer 65:1298–1302

    Article  PubMed  CAS  Google Scholar 

  • Catane R, Schwade JG, Turrisi AT III et al (1979) Pulmonary toxicity after radiation and bleomycin: a review. Int J Radiat Oncol Biol Phys 5:1513–1518

    Article  PubMed  CAS  Google Scholar 

  • Constine LS, Donaldson SS, McDougall IR et al (1984) Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer 53:878–883

    Article  PubMed  CAS  Google Scholar 

  • Constine LS, Marcus R, Chauvenet A et al (2005) Patterns of failure after response-based, dose-dense therapy for intermediate/high risk peciatric Hodgkin’s disease (POG 9425). Int J Radiat Oncol Biol Phys 63:S21–S22

    Article  Google Scholar 

  • Constine LS, Tarbell N, Hudson MM et al (2008) Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 72:24–33

    Article  PubMed  Google Scholar 

  • Dhakal S, Biswas T, Liesveld JL et al (2009) Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 75:188–192

    Article  PubMed  Google Scholar 

  • Donaldson SS (1981) Hodgkin’s disease: treatment with low dose radiation and chemotherapy. Front Radiat Ther Oncol 16:122–133

    PubMed  CAS  Google Scholar 

  • Donaldson SS, Kaplan HS (1982) Complications of treatment of Hodgkin’s disease in children. Cancer Treat Rep 66:977–989

    PubMed  CAS  Google Scholar 

  • Donaldson SS, Glatstein E, Rosenberg SA et al (1976) Pediatric hodgkin’s disease. II. Results of therapy. Cancer 37:2436–2447

    Article  PubMed  CAS  Google Scholar 

  • Donaldson SS, Hudson MM, Lamborn KR et al (2002) VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol 20:3081–3087

    Article  PubMed  CAS  Google Scholar 

  • Dorffel W, Luders H, Ruhl U et al (2003) Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook. Klin Pädiatr 215:139–145

    Article  PubMed  CAS  Google Scholar 

  • Friedmann AM, Hudson MM, Weinstein HJ et al (2002) Treatment of unfavorable childhood Hodgkin’s disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 20:3088–3094

    Article  PubMed  CAS  Google Scholar 

  • Fryer CJ, Hutchinson RJ, Krailo M et al (1990) Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin’s disease in children: a report from the Children’s Cancer Study Group. J Clin Oncol 8:1971–1980

    PubMed  CAS  Google Scholar 

  • Gehan EA, Sullivan MP, Fuller LM et al (1990) The intergroup Hodgkin’s disease in children. A study of stages I and II. Cancer 65:1429–1437

    Article  PubMed  CAS  Google Scholar 

  • Girinsky T, van der Maazen R, Specht L et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277

    Article  PubMed  Google Scholar 

  • Gobbi PG, Cavalli C, Gendarini A et al (1985) Reevaluation of prognostic significance of symptoms in Hodgkin’s disease. Cancer 56:2874–2880

    Article  PubMed  CAS  Google Scholar 

  • Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270:1949–1955

    Article  PubMed  CAS  Google Scholar 

  • Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on advanced Hodgkin’s disease. N Engl J Med 339:1506–1514

    Article  PubMed  CAS  Google Scholar 

  • Hodgson DC, Zhang-Salomons J, Rothwell D et al (2003) Evolution of treatment for Hodgkin’s disease: a population-based study of radiation therapy use and outcome. Clin Oncol (R Coll Radiol) 15:255–263

    Article  CAS  Google Scholar 

  • Hodgson DC, Koh ES, Tran TH et al (2007) Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576–2586

    Article  PubMed  Google Scholar 

  • Hoppe RT, Hanlon AL, Hanks GE et al (1994) Progress in the treatment of Hodgkin’s disease in the United States, 1973 versus 1983. The Patterns of Care Study. Cancer 74:3198–3203

    Article  PubMed  CAS  Google Scholar 

  • Hudson MM, Greenwald C, Thompson E et al (1993) Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin’s disease. J Clin Oncol 11:100–108

    PubMed  CAS  Google Scholar 

  • Hudson MM, Krasin M, Link MP et al (2004) Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin’s disease. J Clin Oncol 22:4541–4550

    Article  PubMed  CAS  Google Scholar 

  • Hull MC, Morris CG, Pepine CJ et al (2003) Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 290:2831–2837

    Article  PubMed  CAS  Google Scholar 

  • Hunger SP, Link MP, Donaldson SS (1994) ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin’s disease: the Stanford experience. J Clin Oncol 12:2160–2166

    PubMed  CAS  Google Scholar 

  • Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59

    Article  PubMed  CAS  Google Scholar 

  • Hutchinson RJ, Fryer CJ, Davis PC et al (1998) MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin’s disease in children: results of the Children’s Cancer Group Phase III Trial. J Clin Oncol 16:897–906

    PubMed  CAS  Google Scholar 

  • Jhanwar YS, Straus DJ (2006) The role of PET in lymphoma. J Nucl Med 47:1326–1334

    PubMed  Google Scholar 

  • Kaplan HS, Rosenberg SA (1966) The treatment of Hodgkin’s disease. Med Clin N Am 50:1591–1610

    PubMed  CAS  Google Scholar 

  • Kelly KM, Hutchinson RJ, Sposto R et al (2002) Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin’s lymphoma: preliminary results from the Children’s Cancer Group Study CCG-59704. Ann Oncol 13(Suppl 1):107–111

    Article  PubMed  Google Scholar 

  • Koh E, Tran T, Heydarian M et al (2005) A dosimetric study of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: implications for second cancer risk and cardiac toxicity. Int J Radiat Oncol Biol Phys 63:S422–S423

    Article  Google Scholar 

  • Kremer LC, van Dalen EC, Offringa M et al (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191–196

    PubMed  CAS  Google Scholar 

  • Kremer LC, van Dalen EC, Offringa M et al (2002) Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 13:503–512

    Article  PubMed  CAS  Google Scholar 

  • Kung FH, Schwartz CL, Ferree CR et al (2006) POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol 28:362–368

    Article  PubMed  CAS  Google Scholar 

  • Landman-Parker J, Pacquement H, Leblanc T et al (2000) Localized childhood Hodgkin’s disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18:1500–1507

    PubMed  CAS  Google Scholar 

  • Lipshultz SE, Colan SD, Gelber RD et al (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815

    Article  PubMed  CAS  Google Scholar 

  • Lipshultz SE, Lipsitz SR, Mone SM et al (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738–1743

    Article  PubMed  CAS  Google Scholar 

  • Maity A, Goldwein JW, Lange B et al (1992) Mediastinal masses in children with Hodgkin’s disease. An analysis of the Children’s Hospital of Philadelphia and the Hospital of the University of Pennsylvania experience. Cancer 69:2755–2760

    Article  PubMed  CAS  Google Scholar 

  • Marina NM, Greenwald CA, Fairclough DL et al (1995) Serial pulmonary function studies in children treated for newly diagnosed Hodgkin’s disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 75:1706–1711

    Article  PubMed  CAS  Google Scholar 

  • Mauch P, Goodman R, Rosenthal DS et al (1979) An evaluation of total nodal irradiation as treatment for stage III A Hodgkin’s disease. Cancer 43:1255–1261

    Article  PubMed  CAS  Google Scholar 

  • Mauch PM, Weinstein H, Botnick L et al (1983) An evaluation of long-term survival and treatment complications in children with Hodgkin’s disease. Cancer 51:925–932

    Article  PubMed  CAS  Google Scholar 

  • Metayer C, Lynch CF, Clarke EA et al (2000) Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol 18:2435–2443

    PubMed  CAS  Google Scholar 

  • Nachman JB, Sposto R, Herzog P et al (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765–3771

    Article  PubMed  Google Scholar 

  • Oberlin O, Leverger G, Pacquement H et al (1992) Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 10:1602–1608

    PubMed  CAS  Google Scholar 

  • Ortin TT, Shostak CA, Donaldson SS (1990) Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 19:873–880

    Article  PubMed  CAS  Google Scholar 

  • Picardi M, De Renzo A, Pane F et al (2007) Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48:1721–1727

    Article  PubMed  Google Scholar 

  • Pihkala J, Saarinen UM, Lundstrom U et al (1996) Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 32A:97–103

    Article  PubMed  CAS  Google Scholar 

  • Polliack A (1995) Late therapy-induced cardiac and pulmonary complications in cured patients with Hodgkin’s disease treated with conventional combination chemo-radiotherapy. Leuk Lymphoma 15(Suppl 1):7–10

    Article  PubMed  Google Scholar 

  • Reinhardt MJ, Herkel C, Altehoefer C et al (2005) Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin’s and non-Hodgkin’s lymphoma patients: when do we really need FDG-PET? Ann Oncol 16:1524–1529

    Article  PubMed  CAS  Google Scholar 

  • Ruhl U, Albrecht M, Dieckmann K et al (2001) Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51:1209–1218

    Article  PubMed  CAS  Google Scholar 

  • Ruhl U, Albrecht MR, Lueders H et al (2004) The German multinational GPOH-HD 95 trial: treatment results and analysis of failures in pediatric Hodgkins disease using combination chemotherapy with and without radiation. Int J Radiat Oncol Biol Phys 60:S131

    Google Scholar 

  • Sackmann-Muriel F, Bonesana AC, Pavlovsky S et al (1981) Hodgkin’s disease in childhood: therapy results in Argentina. Am J Pediatr Hematol Oncol 3:247–254

    PubMed  CAS  Google Scholar 

  • Schellong G, Potter R, Bramswig J et al (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin’s Disease Study Group. J Clin Oncol 17:3736–3744

    PubMed  CAS  Google Scholar 

  • Schonfeld SJ, Gilbert ES, Dores GM et al (2006) Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35, 511 patients. J Natl Cancer Inst 98:215–218

    Article  PubMed  Google Scholar 

  • Schwartz CL, Constine LS, London W et al (2002) POG 9425: response-based, intensively timed therapy for intermediate/high stage (IS/HS) pediatric Hodgkin’s disease. Proc Am Soc Clin Oncol 21:389a

    Google Scholar 

  • Shahidi M, Kamangari N, Ashley S et al (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5

    Article  PubMed  Google Scholar 

  • Sklar C, Whitton J, Mertens A et al (2000) Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85:3227–3232

    Article  PubMed  CAS  Google Scholar 

  • Smith RS, Chen Q, Hudson MM et al (2003) Prognostic factors for children with Hodgkin’s disease treated with combined-modality therapy. J Clin Oncol 21:2026–2033

    Article  PubMed  Google Scholar 

  • Specht L (1996) Prognostic factors in Hodgkin’s disease. Semin Radiat Oncol 6:146–161

    Article  PubMed  Google Scholar 

  • Swerdlow AJ, Barber JA, Hudson GV et al (2000) Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 18:498–509

    PubMed  CAS  Google Scholar 

  • Tebbi CK, Mendenhall N, London WB et al (2006) Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 46:198–202

    Article  PubMed  CAS  Google Scholar 

  • Travis LB, Gospodarowicz M, Curtis RE et al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94:182–192

    Article  PubMed  Google Scholar 

  • Travis LB, Hill D, Dores GM et al (2005) Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97:1428–1437

    Article  PubMed  Google Scholar 

  • van den Berg H, Furstner F, van den BC et al (2004) Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer 42:210–215

    Article  PubMed  Google Scholar 

  • Villani F, Viviani S, Bonfante V et al (2000) Late pulmonary effects in favorable stage I and IIA Hodgkin’s disease treated with radiotherapy alone. Am J Clin Oncol 23:18–21

    Article  PubMed  CAS  Google Scholar 

  • Weiner MA, Leventhal BG, Marcus R et al (1991) Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 9:1591–1598

    PubMed  CAS  Google Scholar 

  • Weiner MA, Leventhal B, Brecher ML et al (1997) Randomized study of intensive MOPP-ABVD with or without low-dose total- nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 15:2769–2779

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Medicine Program, Princess Margaret Hospital, University Health Network, and Dept. of Radiation Oncology, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada

    David C. Hodgson

  2. Department of Clinical Oncology, St Jude Children’s Research Hospital, The University of Tennessee College of Medicine, 332 N Lauderdale St, Mailstop 735, Memphis, TN, 38105-2729, USA

    Melissa M. Hudson

  3. Departments of Radiation Oncology and Pediatrics, James P. Wilmot Cancer Center, University of Rochester Medical Center, 647, Rochester, NY, 14642, USA

    Louis S. Constine

Authors
  1. David C. Hodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa M. Hudson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Louis S. Constine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Hodgson .

Editor information

Editors and Affiliations

  1. Rigshospitalet, Dept. Oncology 3994, Koebenhavns Universitet, Blegdamsvej 9, Koebenhavn, 2100, Denmark

    Lena Specht

  2. Dept. Radiation Oncology, Memorial Sloan-Kettering Cancer Center, York Ave. 1275, New York, 10021, New York, USA

    Joachim Yahalom

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Hodgson, D.C., Hudson, M.M., Constine, L.S. (2011). Pediatric Hodgkin Lymphoma, the Rationale for Radiation Therapy. In: Specht, L., Yahalom, J. (eds) Radiotherapy for Hodgkin Lymphoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78944-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-78944-4_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-78455-5

  • Online ISBN: 978-3-540-78944-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation